BiomeOne® introduced to the members of the German, Austrian and Swiss Societies for Hematology and Medical Oncology
VIENNA, October 11th:
This year, the Annual Meeting of the DGHO (https://www.dgho.de/veranstaltungen/jahrestagung/jahrestagung) was held in Vienna, between the 7-10 October 2022. We had the pleasure of presenting the results of the multi-centric validation study of BiomeOne®, our stool-based microbiome test to predict the response to cancer immunotherapy (immune checkpoint inhibitors). As microbiome diagnostics become more and more of a hot topic, it is important to communicate our latest developments to the medical communities and to collect feedback.
BiomeOne has been CE-IVD marked in May 2022, and is now available for purchase in our website. The test has been released for ICI response prediction in non-small-cell lung cancer, renal cell carcinoma and malignant melanoma patients. Ongoing research aims to further expand the applicability to other tumour types. Read more on BiomeOne.
Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.